Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 29 August 2019, 10:46 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch New "Etak Antimicrobial Wet Wipes" With One Week Lasting Antimicrobial Action
Alcohol-Free Wipe for Eliminating Viruses and Bacteria on Personal Belongings

TOKYO, Aug 29, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch ETAK( Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent ETAK on August 29, 2019 at pharmacies and drugstores countrywide.

ETAK, the main ingredient used in the product, is a long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. An adhesive component of ETAK chemically binds the antimicrobial component to the area wiped with ETAK Antimicrobial Wet Wipes, preserving an antimicrobial effect that lasts for one week.

Eliminating virus and bacteria is a familiar and highly interested theme for consumers, especially mothers with small children.

There were many requests from mothers with small children such as "I want to use ETAK product not only inside the house but also the outside" and "I want to use ETAK product conveniently to the difficult to spray area. In response to these requests, ETAK Antimicrobial Wet Wipes has been commercialized. ETAK Antimicrobial Wet Wipes is alcohol-free so that it is easy to use for families with small children, and it can be used for elimination of viruses and bacteria on personal belongings as well as for cleaning hands and fingertips. In addition, wiping with this product can have antimicrobial barrier for personal belongings and prepare for virus and bacteria. The effect remains even if the area is wiped with water."

As the ETAK brand, containing long-acting antimicrobial agent ETAK, Eisai is marketing ETAK Antimicrobial Spray, a spray for mouth masks, which eliminates viruses and bacteria for 24 hours and ETAK Antimicrobial Spray alpha which can be used for a variety of lifestyle supplies including fabrics such as clothes and stuffed toys as well as kitchenware.

The addition of ETAK Antimicrobial Wet Wipes to the product lineup of ETAK brand will propose new options for elimination of viruses and bacteria as well as antimicrobial action, and we will contribute to further improvement of benefits of consumers who wish to keep those viruses and bacteria at bay.

*This product is not effective on all types of virus and bacteria.
*This product is not a pharmaceutical product nor a quasi-pharmaceutical product.
*ETAK is a registered trademark of CampusMedico Co., Ltd.

About Long-acting Antimicrobial Agent ETAK

ETAK was developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. It is a patented long-acting antimicrobial agent (patent number: 4830075) that combines quaternary ammonium salts, which are also included in hand sanitizers and oral cleansing agents used by dentists, with a silane analogue, an immobilizing agent that functions as an adhesive. ETAK chemically binds the antimicrobial component to the spray area, thereby preserving the antimicrobial effect on the surface of the target object.


Contact:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 14:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: